Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Director | June 10, 2026 | June 12, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Exe V-P & Pres, MRL | February 25, 2013 | February 27, 2013 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.97 · Expires 2036-06-10 | Direct | 19,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 19,000 · Balance 19,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.
Merck & Co., Inc.
Report date February 25, 2013 · Filed February 27, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 189,608.9037 |
Reported balance
After 2013-02-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2013-02-25 · Grant · Acquired 18,903 · Balance 189,608.9037 F1: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/2010. Performance shares were paid out at 107 percent of target awards. F2: Holdings include shares acquired in dividend reinvestment transactions. |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy 401(k) | 1,348.1191 |
Reported balance
Holding disclosure · report date 2013-02-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,348.1191 F3: Includes shares acquired and dividends through January 8, 2013 in the MSD Employee Savings and Security Plan, a 401(k) plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/2010. Performance shares were paid out at 107 percent of target awards.
F2: Holdings include shares acquired in dividend reinvestment transactions.
F3: Includes shares acquired and dividends through January 8, 2013 in the MSD Employee Savings and Security Plan, a 401(k) plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 17:17 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001689375-26-000044 · wk-form4_1781299039.xml · derivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 08:08 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001689375-25-000033 · wk-form4_1749730123.xml · derivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 11, 2025 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 16:38 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001689375-24-000037 · wk-form4_1718397487.xml · derivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 13, 2024 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 16:31 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,918 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001689375-24-000032 · wk-form4_1717619480.xml · derivative · entry 2 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,918 shares Expires 2032-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option fully vested on June 2, 2023. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 16:31 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 11,918 | $6.06 | $72,223.08 |
DisclosureSEC source: 0001689375-24-000032 · wk-form4_1717619480.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 16, 2024 16:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 25,000 | $14.59 | $364,672.50 |
DisclosureSEC source: 0001689375-24-000029 · wk-form4_1715891608.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,412 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.465 to $14.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2024 Filed Jun 18, 2025 16:32 UTC Amendment | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 25,000 | $14.59 | $364,672.50 |
DisclosureSEC source: 0001689375-25-000035 · wk-form4a_1750278753.xml · nonDerivative · entry 2 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,412 F2 · price: On May 16, 2024, the Reporting Person filed a Form 4 that reported the purchase of 25,000 shares of common stock on May 14, 2024 and inadvertently omitted to report the purchase of an additional 25,000 shares of common stock on May 13, 2024. This Form 4/A reports the purchase of those 25,000 additional shares of common stock and to correct certain totals. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.465 to $14.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: On May 16, 2024, the Reporting Person filed a Form 4 that reported the purchase of 25,000 shares of common stock on May 14, 2024 and inadvertently omitted to report the purchase of an additional 25,000 shares of common stock on May 13, 2024. This Form 4/A reports the purchase of those 25,000 additional shares of common stock and to correct certain totals. Read SEC document |
| May 13, 2024 Filed Jun 18, 2025 16:32 UTC Amendment | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 25,000 | $14.68 | $367,010.00 |
DisclosureSEC source: 0001689375-25-000035 · wk-form4a_1750278753.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,412 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.63 to $14.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · price: On May 16, 2024, the Reporting Person filed a Form 4 that reported the purchase of 25,000 shares of common stock on May 14, 2024 and inadvertently omitted to report the purchase of an additional 25,000 shares of common stock on May 13, 2024. This Form 4/A reports the purchase of those 25,000 additional shares of common stock and to correct certain totals. F2 · balance_after: On May 16, 2024, the Reporting Person filed a Form 4 that reported the purchase of 25,000 shares of common stock on May 14, 2024 and inadvertently omitted to report the purchase of an additional 25,000 shares of common stock on May 13, 2024. This Form 4/A reports the purchase of those 25,000 additional shares of common stock and to correct certain totals. Read SEC document |
| May 09, 2024 Filed May 10, 2024 16:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 2,200 | $14.25 | $31,340.98 |
DisclosureSEC source: 0001689375-24-000028 · wk-form4_1715373322.xml · nonDerivative · entry 2 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,412 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.11 to $14.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2024 Filed May 10, 2024 16:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 2,276 | $14.04 | $31,964.60 |
DisclosureSEC source: 0001689375-24-000028 · wk-form4_1715373322.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,212 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.81 to $14.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 16:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 2,600 | $13.57 | $35,289.80 |
DisclosureSEC source: 0001689375-24-000021 · wk-form4_1712781308.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,936 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.49 to $13.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 16:31 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 1,512 | $13.75 | $20,793.93 |
DisclosureSEC source: 0001689375-24-000020 · wk-form4_1712003472.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,336 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.70 to $13.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 26, 2024 Filed Mar 26, 2024 17:57 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 2,750 | $13.64 | $37,509.18 |
DisclosureSEC source: 0001689375-24-000019 · wk-form4_1711490229.xml · nonDerivative · entry 3 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,824 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.62 to $13.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 25, 2024 Filed Mar 26, 2024 17:57 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 3,180 | $13.36 | $42,472.08 |
DisclosureSEC source: 0001689375-24-000019 · wk-form4_1711490229.xml · nonDerivative · entry 2 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,074 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.22 to $13.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 22, 2024 Filed Mar 26, 2024 17:57 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 3,118 | $13.76 | $42,900.56 |
DisclosureSEC source: 0001689375-24-000019 · wk-form4_1711490229.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,894 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.68 to $13.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 21, 2024 Filed Mar 21, 2024 16:31 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 704 | $13.24 | $9,317.65 |
DisclosureSEC source: 0001689375-24-000018 · wk-form4_1711053067.xml · nonDerivative · entry 3 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,776 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.11 to $13.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 20, 2024 Filed Mar 21, 2024 16:31 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 1,128 | $12.66 | $14,280.93 |
DisclosureSEC source: 0001689375-24-000018 · wk-form4_1711053067.xml · nonDerivative · entry 2 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,072 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.55 to $12.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 16:31 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 900 | $12.66 | $11,396.97 |
DisclosureSEC source: 0001689375-24-000018 · wk-form4_1711053067.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,944 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.59 to $12.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 16:05 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $14.67 | $0.00 |
DisclosureSEC source: 0001104659-23-070329 · tm2318445-1_4seq1.xml · derivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 16:02 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 11,918 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001104659-22-068506 · tm2217670-5_4seq1.xml · derivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,918 Underlying: Common Stock · 11,918 shares Expires 2032-06-02 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 2, 2022 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 18:59 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 11,918 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001104659-21-132477 · tm2131250-18_4seq1.xml · derivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,918 Underlying: Common stock · 11,918 shares Expires 2031-10-28 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of October 28, 2021 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 22:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 18,903 | $42.52 | $803,755.56 |
DisclosureSEC source: 0001225208-13-005766 · doc4.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,608.9037 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/2010. Performance shares were paid out at 107 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 224,000 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001225208-12-022533 · doc4.xml · derivative · entry 8 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 224,000 shares Expires 2019-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 96,000 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-12-022533 · doc4.xml · derivative · entry 7 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,000 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-12-022533 · doc4.xml · derivative · entry 6 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 420,000 | $45.50 | $19,110,672.00 |
DisclosureSEC source: 0001225208-12-022533 · doc4.xml · nonDerivative · entry 4 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,705.9037 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.4500 to $45.6109, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 96,000 | $35.09 | $3,368,640.00 |
DisclosureSEC source: 0001225208-12-022533 · doc4.xml · nonDerivative · entry 3 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,705.9037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 100,000 | $31.84 | $3,184,000.00 |
DisclosureSEC source: 0001225208-12-022533 · doc4.xml · nonDerivative · entry 2 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,705.9037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2012 Filed Nov 6, 2012 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 224,000 | $23.45 | $5,252,800.00 |
DisclosureSEC source: 0001225208-12-022533 · doc4.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,705.9037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 219,378 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-12-011192 · doc4.xml · derivative · entry 4 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,378 Underlying: Common Stock · 219,378 shares Expires 2022-05-01 F4 · derivative.exercise_date: The option vests in three equal annual installments beginning May 2, 2013. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 15,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-011192 · doc4.xml · derivative · entry 3 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,271 Underlying: Common Stock · 15,271 shares Expires 2015-05-02 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-011192 · doc4.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,705.9037 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 28, 2012 Filed Mar 1, 2012 20:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 16,701 | $38.38 | $640,984.38 |
DisclosureSEC source: 0001225208-12-006223 · doc4.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,705.9037 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 2/27/09. Performance shares were paid out at 117 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2011 Filed May 6, 2011 14:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 223,881 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-11-013366 · doc4.xml · derivative · entry 4 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,881 Underlying: Common Stock · 223,881 shares Expires 2021-05-03 F4 · derivative.exercise_date: The option vests in three equal annual installments beginning May 4, 2012. Read SEC document |
| May 04, 2011 Filed May 6, 2011 14:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 16,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-013366 · doc4.xml · derivative · entry 3 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,411 Underlying: Common Stock · 16,411 shares Expires 2014-05-04 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 20:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 21,600 | $32.19 | $695,304.00 |
DisclosureSEC source: 0001225208-11-007806 · doc4.xml · derivative · entry 4 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,600 shares Expires 2011-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 20:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 8,530 | $32.19 | $274,580.70 |
DisclosureSEC source: 0001225208-11-007806 · doc4.xml · nonDerivative · entry 2 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,004.9037 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 20:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 21,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007806 · doc4.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,534.9037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2011 Filed Feb 24, 2011 17:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 18,037 | $32.34 | $583,316.58 |
DisclosureSEC source: 0001225208-11-007024 · doc4.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,934.9037 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 2/29/08. Performance shares were paid out at 122 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 07, 2010 Filed May 11, 2010 20:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 180,072 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-10-012614 · doc4.xml · derivative · entry 4 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,072 Underlying: Common Stock · 180,072 shares Expires 2020-05-06 F4 · derivative.exercise_date: The option vests in three equal annual installments beginning May 7, 2011. Read SEC document |
| May 07, 2010 Filed May 11, 2010 20:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 29,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-012614 · doc4.xml · derivative · entry 3 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,860 Underlying: Common Stock · 29,860 shares Expires 2013-05-07 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 18:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRSU - Leader Shares · Derivative | 16,000 | $37.27 Strike: $0.00 | $596,320.00 |
DisclosureSEC source: 0001225208-10-007060 · doc4.xml · derivative · entry 7 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2010-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 18:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 21,600 | $37.27 Strike: $0.00 | $805,032.00 |
DisclosureSEC source: 0001225208-10-007060 · doc4.xml · derivative · entry 6 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,600 shares Expires 2010-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 18:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 8,693 | $37.27 | $323,988.11 |
DisclosureSEC source: 0001225208-10-007060 · doc4.xml · nonDerivative · entry 4 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,897.9037 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 18:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 6,484 | $37.27 | $241,658.68 |
DisclosureSEC source: 0001225208-10-007060 · doc4.xml · nonDerivative · entry 3 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,590.9037 Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 18:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-007060 · doc4.xml · nonDerivative · entry 2 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,074.9037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 18:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 21,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-007060 · doc4.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,074.9037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2010 Filed Jan 26, 2010 19:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 17,833 | $37.72 | $672,660.76 |
DisclosureSEC source: 0001225208-10-002267 · doc4.xml · nonDerivative · entry 1 KIM PETER S · CIK 0001181180 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,474.9037 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/02/2007. Performance shares were paid out at 120 percent of target awards. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:18 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 224,000 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001209191-09-051310 · c92131_4x0.xml · derivative · entry 15 KIM PETER S · CIK 0001181180 · Exec. V-P and Pres., MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 224,000 shares Expires 2019-04-23 F5 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F5 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:18 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 115,200 | $0.00 Strike: $44.30 | $0.00 |
DisclosureSEC source: 0001209191-09-051310 · c92131_4x0.xml · derivative · entry 14 KIM PETER S · CIK 0001181180 · Exec. V-P and Pres., MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,200 shares Expires 2018-02-28 F5 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F5 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.